Skip to main content

Table 1 Specific deletion of Brca1 induces mammary tumors with activation of Pdgfrβ signaling in p18- and p16-deficient mice

From: PDGFRβ is an essential therapeutic target for BRCA1-deficient mammary tumors

Genotype1 Mammary tumor # Metastatic tumor #3 EMT+ tumor #4 Pdgfrβ+ tumor #5 p-Pkcα+ tumor #6 p-Fra1+ tumor #6
WT 0/9      
p18−/− 7/15 (47%) 0/7 2/7 (29%) 2/7 (29%) 2/7 (29%) 2/7 (29%)
Brca1MGKO2 1/13 (8%) 0/1 1/1 1/1 1/1 1/1
p18-/-;Brca1MGKO 11/15 (73%) 4/11 (36%) 9/11 (82%)* 9/11 (82%)* 9/11 (82%)* 9/11 (82%)*
p16-/- 0/20      
p16-/-;Brca1MGKO 6/10 (60%) 3/6 (50%) 6/6 (100%) 6/6 (100%) 6/6 (100%) 6/6 (100%)
  1. 1All mice were in Balb/c-B6 mixed background
  2. 2Brca1MGKO, Brca1f/f;MMTV-Cre, or Brca1f/-;MMTV-Cre
  3. 3Metastasis was found in the lung
  4. 4At least two EMT markers (decreased E-Cad, increased Vim, Fn1, Sma or Cd29) or two EMT-TFs, which included Twist, Slug, Snail, Foxc1, and Foxc2, were detected in > 2% tumor cells by IHC
  5. 5Tumors that had > 2% positive Pdgfrβ cells by IHC, or primary p18-/-;Brca1MGKO and p16-/-;Brca1MGKO tumor cells at passage 1 expressed fivefolds more Pdgfrβ than p18-/- tumor cells by western blot analysis (see Fig. 2e)
  6. 6Tumors that had > 2% positive p-Pkcα or p-Fra1 cells by IHC
  7. *A significance from p18-/-;Brca1MGKO and p18-/- tumors by a two-tailed Fisher’s exact test